Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Open original source
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Open original source